Table of Contents

company-logo

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Actinium Pharmaceuticals Dividend Announcement

• Actinium Pharmaceuticals does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Actinium Pharmaceuticals dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Actinium Pharmaceuticals Dividend History

Actinium Pharmaceuticals Dividend Yield

Actinium Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Actinium Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

Actinium Pharmaceuticals Financial Ratios

P/E ratio-1.10
PEG ratio0.82
P/B ratio1.18
ROE-100.85%
Payout ratio0.00%
Current ratio10.25
Quick ratio10.25
Cash Ratio10.14

Actinium Pharmaceuticals Dividend FAQ

Does Actinium Pharmaceuticals stock pay dividends?
Actinium Pharmaceuticals does not currently pay dividends to its shareholders.
Has Actinium Pharmaceuticals ever paid a dividend?
No, Actinium Pharmaceuticals has no a history of paying dividends to its shareholders. Actinium Pharmaceuticals is not known for its dividend payments.
Why doesn't Actinium Pharmaceuticals pay dividends?
There are several potential reasons why Actinium Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Actinium Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Actinium Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Actinium Pharmaceuticals a dividend aristocrat?
Actinium Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Actinium Pharmaceuticals a dividend king?
Actinium Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Actinium Pharmaceuticals a dividend stock?
No, Actinium Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Actinium Pharmaceuticals stocks?
To buy Actinium Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Actinium Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.